NCT05832684View on ClinicalTrials.gov

Safety and Efficacy of ZVS101e in Patients With Bietti 's Crystalline Dystrophy

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

February 20, 2023

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2028

Conditions
Bietti's Crystalline Dystrophy
Interventions
DRUG

ZVS101e

ZVS101e contains recombinant adeno-associated virus serotype 8 (rAAV8) vectors which carry human wild type CYP4V2 gene.

Trial Locations (3)

100191

Peking University Third Hospital, Beijing

300392

Tianjin Medical University Eye Hospital, Tianjin

Unknown

West China Hospital, Sichuan University, Chengdu

All Listed Sponsors
lead

Chigenovo Co., Ltd

NETWORK